{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:37:39Z","timestamp":1785796659139,"version":"3.56.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This trial served as a proof-of-concept for whether inhibition of protein kinase C iota (PKC\u03b9) with auranofin and sirolimus provide antineoplastic effects in patients with recurrent high-grade serous ovarian cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This drug combination was administered to patients with recurrent high-grade serous ovarian cancer. Dosing was based on unpublished phase 1 data and consisted of auranofin 6\u00a0mg and sirolimus 5\u00a0mg both orally per day of a 28-day cycle. The primary endpoint was tumor response. Available tumor tissue was assessed for PKC\u03b9 protein expression by immunohistochemistry (IHC) and PRKCI copy number by fluorescence in-situ hybridization (FISH) after the start of cancer therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Twenty-two patients were enrolled, and 21 were evaluable for all clinical trial endpoints. One patient was unevaluable because she did not receive a full chemotherapy cycle. No tumor responses were seen in the first 21 patients, resulting in early trial termination per\n                      <jats:italic toggle=\"yes\">a priori<\/jats:italic>\n                      trial design. The median progression-free survival was 2.1 months (95% CI: 1.8-3.7). The median overall survival was 4.4 months (95% CI: 2.6-12.5). Fourteen (67%) patients had at least one grade 3 or worse adverse event. Nineteen of 21 evaluable patients had available tumor tissue, which showed the median PKC\u03b9 copy number averaged per cell of 3 (range: 2 to 7), and PKC\u03b9 expression (at least 1+) in all.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>As prescribed here, auranofin and sirolimus manifested no antineoplastic activity in patients with recurrent high-grade serous ovarian cancer that expressed PKC\u03b9.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/coc.0000000000001263","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T15:00:33Z","timestamp":1760972433000},"page":"238-242","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["A Phase 2 Trial of Protein Kinase C Iota Inhibition With the Combination of Auranofin and Sirolimus in Patients With Recurrent Ovarian Cancer"],"prefix":"10.1097","volume":"49","author":[{"given":"Aminah","family":"Jatoi","sequence":"first","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan R.","family":"Foster","sequence":"additional","affiliation":[{"name":"Department of Health Sciences Research, Section of Cancer Center Statistics, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Wahner Hendrickson","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Block","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. John","family":"Weroha","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik J.","family":"Asmus","sequence":"additional","affiliation":[{"name":"Department of Health Sciences Research, Section of Cancer Center Statistics, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"Murray","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan P.","family":"Fields","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"R1-20260423","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2013.10.023","article-title":"Atypical protein kinase C\u03b9 as a human oncogene and therapeutic target","volume":"88","author":"Parker","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"R2-20260423","doi-asserted-by":"crossref","first-page":"100754","DOI":"10.1016\/j.jbior.2020.100754","article-title":"Recurrent copy number gains drive PKC\u03b9 expression and PKC\u03b9-dependent oncogenic signaling in human cancers","volume":"78","author":"Liu","year":"2020","journal-title":"Adv Biol Regul"},{"key":"R3-20260423","doi-asserted-by":"crossref","first-page":"110054","DOI":"10.1016\/j.celrep.2021.110054","article-title":"Protein kinase C\u03b9 and SRC signaling define reciprocally related subgroups of glioblastoma with distinct therapeutic vulnerabilities","volume":"37","author":"Kenchappa","year":"2021","journal-title":"Cell Rep"},{"key":"R4-20260423","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1097\/CAD.0000000000000009","article-title":"Phase I dose escalation study of the PKC\u03b9 inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer","volume":"24","author":"Mansfield","year":"2013","journal-title":"Anticancer Drugs"},{"key":"R5-20260423","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000369257","article-title":"A mixed-methods feasibility trial of protein kinase C iota inhibition with auranofin in asymptomatic ovarian cancer patients","volume":"88","author":"Jatoi","year":"2015","journal-title":"Oncology"},{"key":"R6-20260423","first-page":"1373","article-title":"Simultaneous inhibition of atypical protein kinase-C and mTOR impedes bladder cancer cell progression","volume":"56","author":"Patel","year":"2020","journal-title":"Int J Oncol"},{"key":"R7-20260423","doi-asserted-by":"crossref","first-page":"pe27","DOI":"10.1126\/scisignal.267pe27","article-title":"New insights into mTOR signaling: mTORC2 and beyond","volume":"2","author":"Alessi","year":"2009","journal-title":"Sci Signal"},{"key":"R8-20260423","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ccell.2019.07.002","article-title":"Protein kinase Ci and Wnt\/b-catenin signaling: alternative pathways to Kras\/Trp53-driven lung adenocarcinoma","volume":"36","author":"Ning","year":"2019","journal-title":"Cancer Cell"},{"key":"R9-20260423","first-page":"539","article-title":"Characterization of the role of protein kinase C isozymes in colon carcinogenesis using transgenic mouse models","volume":"233","author":"Fields","year":"2003","journal-title":"Methods Mol Biol"},{"key":"R10-20260423","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.3390\/pharmaceutics13111748","article-title":"Activators and inhibitors of protein kinase C (PKC): their applications in clinical trials","volume":"13","author":"Kawano","year":"2021","journal-title":"Pharmaceutics"},{"key":"R11-20260423","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/labinvest.2017.70","article-title":"Phosphorylated mTOR and YAP serve as prognostic markers and therapeutic targets in gliomas","volume":"97","author":"Liu","year":"2017","journal-title":"Lab Invest"},{"key":"R12-20260423","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41467-024-55660-6","article-title":"YAP-driven malignant reprogramming of oral epithelial stem cells at single cell resolution","volume":"16","author":"Faraji","year":"2025","journal-title":"Nat Commun"},{"key":"R13-20260423","doi-asserted-by":"crossref","first-page":"eabq5931","DOI":"10.1126\/scitranslmed.abq5931","article-title":"Protein kinase C\u03b9 mediates immunosuppression in lung adenocarcinoma","volume":"14","author":"Yin","year":"2022","journal-title":"Sci Trans Med"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000001263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T12:12:04Z","timestamp":1776946324000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000001263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000001263","relation":{},"ISSN":["0277-3732","1537-453X"],"issn-type":[{"value":"0277-3732","type":"print"},{"value":"1537-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"assertion":[{"value":"2025-09-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}